Centogene N.V.
MUN:39K Voorraadrapport
Marktkapitalisatie: €3.3m
Centogene Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6 Centogene heeft een totaal eigen vermogen van €-25.3M en een totale schuld van €65.8M, wat de schuld-eigenvermogensverhouding op -260.1% brengt. De totale activa en totale passiva bedragen respectievelijk €77.2M en €102.4M.
Belangrijke informatie
-260.1%
Verhouding schuld/eigen vermogen
Rente dekkingsratio n/a Contant €19.10m Aandelen -€25.28m Totaal verplichtingen €102.44m Totaal activa €77.16m
Recente financiële gezondheidsupdates Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024 Centogene N.V. announced delayed 20-F filing May 03
Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency Jun 16
Centogene Regains Compliance with Nasdaq Listing Requirements Feb 08
Centogene Receives Nasdaq Non-Compliance Notice Dec 17
Toon alle updates
Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer Oct 12
Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD) Sep 26 Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024
Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors Aug 02
Centogene N.V. Provides Earnings Guidance for the Year 2024 May 17
Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients May 11 Centogene N.V. announced delayed 20-F filing May 03
New minor risk - Financial data availability Mar 25
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 Jan 18
Centogene N.V. Announces Changes to Supervisory Board Dec 18
New major risk - Financial position Dec 14
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone Dec 14
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism Nov 15
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering Oct 11
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023 Sep 08
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients Sep 02
Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board Aug 19
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort Jul 13 Centogene N.V. announced that it expects to receive $30 million in funding from Lifera Jun 29
Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency Jun 16
Centogene N.V., Annual General Meeting, Jun 30, 2023 Jun 14
Centogene N.V., Annual General Meeting, Jun 30, 2023 Jun 13
Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023 May 20
Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021) May 18
Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023 May 17
Centogene Regains Compliance with Nasdaq Listing Requirements Feb 08
Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH Jan 31
Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023 Jan 20
Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics Jan 12
Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022 Dec 23
Centogene Receives Nasdaq Non-Compliance Notice Dec 17
Centogene N.V. Announces Changes to Supervisory Board Nov 22
Centogene Launches Rare and Neurodegenerative Disease Biodata Network Nov 04
First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021) Jul 16
Centogene N.V. Reaffirms Earnings Guidance for the Year 2022 Jul 16 Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director
Centogene N.V., Annual General Meeting, Jun 22, 2022 Jun 08
Centogene N.V., Annual General Meeting, Jun 22, 2022 Jun 07
Centogene N.V. Provides Earnings Guidance for the Year 2022 Mar 31 Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.
Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases Jan 05
Centogene N.V. Provides Earnings Guidance for the Full Year 2021 Nov 25
Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021 Sep 09
Executive Officer Richard Stoffelen has left the company Jul 01
First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020) Jun 18
Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021 Jun 17
Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia Jun 03
Centogene N.V. Launches New CentoXome Jun 02
Centogene N.V. Extends Global Parkinson’s Disease Study May 12
Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank May 07
Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank May 06
Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019) Apr 17
Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study Mar 11
New 90-day high: €10.55 Feb 19
New 90-day low: €9.06 Jan 29
Third quarter 2020 earnings released: €0.27 loss per share Dec 17 Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020
Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport Nov 27
Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency Nov 26
Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands Oct 15
Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation Oct 06
First half earnings released Sep 25
New 90-day low: €8.50 Sep 24
Centogene Opens Walk-In COVID-1 Testing Facility At Düsseldorf Airport Sep 24
Centogene N.V. to Report First Half, 2020 Results on Sep 23, 2020 Sep 17
New 90-day low - €9.84 Aug 29
New 90-day low - €10.35 Aug 12
Centogene N.V. has completed a Follow-on Equity Offering in the amount of $49 million. Jul 10
Centogene N.V.(NasdaqGM:CNTG) dropped from Russell Microcap Value Index Jul 03
Centogene N.V.(NasdaqGM:CNTG) dropped from Russell 3000 Value Index Jul 02
Analyse van de financiële positie
Kortlopende schulden: 39K heeft een negatief eigen vermogen , wat een ernstiger situatie is dan dat kortetermijnactiva de kortetermijnschulden niet dekken.
Langlopende schulden: 39K heeft een negatief eigen vermogen, wat een ernstiger situatie is dan wanneer de kortetermijnactiva de langetermijnschulden niet dekken.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 39K heeft negatief eigen vermogen , wat een ernstiger situatie is dan een hoog schuldenniveau.
Schuld verminderen: 39K heeft een negatief eigen vermogen, dus we hoeven niet te controleren of de schuld in de loop van de tijd is afgenomen.
Analyse van de cashflow Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Er zijn onvoldoende gegevens om te bepalen of 39K voldoende cash runway heeft op basis van de huidige vrije kasstroom .
Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 39K voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}